All Pharma News
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
PRESS RELEASE
26 Mar 2024
Share Share
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
PRESS RELEASE
28 Feb 2024
Share Share
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
PRESS RELEASE
27 Feb 2024
Share Share
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PRESS RELEASE
05 Feb 2024
Share Share
Beam Therapeutics Appoints Christi Shaw to its Board of Directors

Beam Therapeutics Appoints Christi Shaw to its Board of Directors
PRESS RELEASE
14 Dec 2023
Share Share
Beam Therapeutics Reports Third Quarter 2023 Financial Results

Beam Therapeutics Reports Third Quarter 2023 Financial Results
PRESS RELEASE
08 Nov 2023
Share Share
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
PRESS RELEASE
08 Nov 2023
Share Share
Beam offloads Verve rights to Lilly for up to $600M

Beam offloads Verve rights to Lilly for up to $600M
Max Bayer FIERCE BIOTECH
31 Oct 2023
Share Share
Beam Therapeutics Presents Data Highlighting Utility and Durability of BEAM-301

Beam Therapeutics Presents Data Highlighting Utility and Durability of BEAM-301
PRESS RELEASE
25 Oct 2023
Share Share
Beam Therapeutics Announces Portfolio Prioritization & Strategic Restructuring

Beam Therapeutics Announces Portfolio Prioritization & Strategic Restructuring
PRESS RELEASE
19 Oct 2023
Share Share